澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ISLAND PHARMACEUTICALS LTD

0.420

0.000

成交量：12.03万

成交额：5.24万

市值：1.13亿

市盈率：-18.57

高：0.450

开：0.450

低：0.420

收：0.420

52周最高：0.630

52周最低：0.120

股本：2.69亿

流通股本：1.11亿

量比：0.20

换手率：0.11%

股息：- -

股息率：- -

每股收益(TTM):-0.023

每股收益(LYR):-0.023

净资产收益率：-90.37%

总资产收益率：-49.16%

市净率：15.79

市盈率(LYR):-18.57

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Island Pharmaceuticals：美国FDA通知需额外时间完成对公司近期提交材料的回复

ISLAND PHARMACEUTICALS LTD 就Galidesivir依据FDA动物规则开发路径寻求进一步澄清

Island Pharmaceuticals Ltd将就拟议临床研究设计寻求指导，Galidesivir有望获得优先审评券资格

ISLAND PHARMACEUTICALS LTD：FDA批准在加利昔韦开放性试验性新药申请下召开C类会议

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ILA.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ILA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","market":"AU","secType":"STK","nameCN":"ISLAND PHARMACEUTICALS LTD","latestPrice":0.42,"timestamp":1770613920000,"preClose":0.42,"halted":0,"volume":120296,"delay":0,"changeRate":0,"nameEN":"ISLAND PHARMACEUTICALS LTD","floatShares":110756995,"shares":269052397,"eps":-0.022614,"marketStatus":"未开盘","change":0,"latestTime":"02-09 16:12:00 AEDT","open":0.45,"high":0.45,"low":0.42,"amount":52405,"amplitude":0.071429,"askPrice":0.43,"askSize":10119,"bidPrice":0.415,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.022614,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.42,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.201999,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","floatShares":110756995,"roa":"-49.16%","roe":"-90.37%","lyrEps":-0.022614,"volumeRatio":0.201999,"shares":269052397,"dividePrice":0,"high":0.45,"amplitude":0.071429,"preClose":0.42,"low":0.42,"week52Low":0.12,"pbRate":"15.79","psRate":"950.32","week52High":0.63,"institutionHeld":0,"latestPrice":0.42,"committee":-0.005915,"eps":-0.022614,"divideRate":0,"volume":120296,"delay":0,"ttmEps":-0.022614,"open":0.45,"prevYearClose":0.43,"prevWeekClose":0.42,"prevMonthClose":0.39,"prevQuarterClose":0.43,"fiveDayClose":0.39,"twentyDayClose":0.45,"sixtyDayClose":0.435,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ILA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ILA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ILA.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151552066","title":"Island Pharmaceuticals：美国FDA通知需额外时间完成对公司近期提交材料的回复","url":"https://stock-news.laohu8.com/highlight/detail?id=1151552066","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151552066?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 05:43","pubTimestamp":1767562991,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd（ASX: ILA）近日披露，美国食品药品监督管理局（FDA）已向公司发出通知，表示需要更多时间来最终确定对其近期提交材料的正式回复。这一进展意味着FDA对该公司提交内容的审核流程仍在进行中，但完成评估所需时间较原预期有所延长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"1149987014","title":"ISLAND PHARMACEUTICALS LTD 就Galidesivir依据FDA动物规则开发路径寻求进一步澄清","url":"https://stock-news.laohu8.com/highlight/detail?id=1149987014","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149987014?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 05:43","pubTimestamp":1767562991,"startTime":"0","endTime":"0","summary":"ISLAND PHARMACEUTICALS LTD 已就抗病毒药物Galidesivir依据美国食品药品监督管理局（FDA）的“动物规则”进行开发的路径，向监管机构寻求进一步的说明和澄清。此举旨在更清晰地理解在该法规框架下推进药物研发的具体要求和流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"1170573251","title":"Island Pharmaceuticals Ltd将就拟议临床研究设计寻求指导，Galidesivir有望获得优先审评券资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1170573251","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170573251?lang=zh_cn&edition=fundamental","pubTime":"2025-09-19 07:32","pubTimestamp":1758238336,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd宣布，公司将就拟议的临床研究设计方案寻求监管机构指导，同时评估其抗病毒药物Galidesivir获得优先审评券的资格。\n该公司此举旨在推进Galidesivir的临床开发进程，通过与监管部门的沟通确保研究设计符合要求。优先审评券机制可为符合条件的药物提供加速审批通道，有助于缩短上市时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"1181195802","title":"ISLAND PHARMACEUTICALS LTD：FDA批准在加利昔韦开放性试验性新药申请下召开C类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1181195802","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181195802?lang=zh_cn&edition=fundamental","pubTime":"2025-09-19 07:31","pubTimestamp":1758238272,"startTime":"0","endTime":"0","summary":"ISLAND PHARMACEUTICALS LTD宣布，美国食品药品监督管理局（FDA）已批准在其药物加利昔韦的开放性试验性新药申请框架下召开C类会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ILA.AU\",params:#limit:6,delay:true,,,undefined,":[]}}